Correlia Biosystems

Executive Summary

Correlia Biosystems, a Berkeley-based biotechnology company founded in 2017, is commercializing the PIXI platform, a benchtop automated immunoassay system that enables rapid, highly sensitive protein quantification. The platform addresses a critical need in clinical diagnostics and life sciences research by providing microscale analysis with improved speed and efficiency compared to traditional methods. Despite limited publicly available information on funding and revenue, the company's focus on proteomics and point-of-care diagnostics aligns with growing market demands for decentralized testing and personalized medicine. Correlia's technology has the potential to disrupt the immunoassay market by lowering costs and turnaround times, though execution risks remain typical for early-stage diagnostics firms.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of PIXI platform to early access customers40% success
• Q2 2027FDA 510(k) clearance or CE marking for initial clinical menu30% success
• Q4 2026Strategic partnership with a major diagnostics or pharma company50% success